ArticleThe Indian journal of medical research2025
Genotypic distribution & clinical profile of chronic hepatitis B cases: insights from a tertiary care hospital in North India.
Article in The Indian journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hepatitis B seroprevalence and knowledge awareness among spouses of reported Hepatitis B cases in Quzhou city: A cross-sectional study.Human vaccines & immunotherapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Objectives India is considered a region with intermediate to high endemicity for the carriage of Hepatitis B surface antigen (HBsAg). Epidemiological updates are crucial to monitor the progress towards the global commitment to eliminate hepatitis by 2030. This study was designed to analyse the demographic, epidemiological, laboratory, virological, clinical, and genotypic characteristics of the patients with Chronic Hepatitis B (CHB) in North India. Methods One hundred and eighty-three HBsAg-positive patients were enrolled in the study between October 2019 and October 2022. Inclusion criteria required patients to have HBsAg detectable in serum for more than six months. The genotype of Hepatitis B virus (HBV) was determined by using polymerase chain reaction (PCR)- based method. To validate the findings, 20 samples were selected for HBV DNA polymerase genes (S/POL) sequencing, which is crucial for accurately classifying of the virus and its genotypic characteristics. Sequences were manually edited with the BioEdit Sequence Editor (version 7.2.5) and analysed via BLAST. Results Among 183 HBsAg-positive chronic liver disease patients, 77.5 per cent clinically presented as HBeAg negative chronic hepatitis. The identified genotypes were predominantly D (170; 92.2%), followed by A (11; 6%) and C (2; 1.1%). Of the total patients, 102 (55.7%) were male, with the majority within the 0-45 years age group (83.4%). The most common risk factor was surgical intervention (77; 42.1%), followed by tattooing and body piercing (39; 21.3%), blood transfusion (14; 7.7%), dialysis (33; 18%), mother-to-child transmission (4; 2.2%), IV drug abuse (10; 5.5%), and dental procedures (3; 1.6%). Familial transmission was observed in 11.8 per cent of spouses. Interpretation & conclusions The study highlighted that genotype D was the most prevalent and acquired commonly through the parenteral routes, with severe disease phase, while genotype A was the next frequent genotype associated with vertical or familial spread, with the most patients seen in the immune-tolerant phase.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.